Repetto G, Poggi H, Harris P, Navarro H, Sánchez I, Guiraldes E, Pérez M A, Boza M L, Hunter B, Wevar M E, Mediavilla M, Foradori A
Departamento de Pediatría y Laboratorio de Desarrollo y Biología Molecular, Facultad de Medicina, Pontificia Universidad Católica de Chile.
Rev Med Chil. 2001 Aug;129(8):841-7.
Cystic fibrosis (CF) is an autosomal recessive disease caused by mutations in the CFTR gene, that codes for a chloride channel located in the apical surface of epithelial cells. The main role of this protein is the regulation of chloride transport, and secondarily, of sodium and water to the extracellular space. More than 900 gene mutations have been described, and their relative frequency in different populations depends on their ethnic origin.
To report the findings of Chilean patients with cystic fibrosis, in whom the presence of 20 common mutations was analyzed.
Fifty seven patients with established diagnosis or suspicion of CF were studied. The simultaneous identification of 20 mutations and the normal delta F508 allele was done using polymerase chain reactions with a commercial assay.
Eight mutations were found. Fifty patients fulfilled diagnostic criteria proposed by the Consensus Panel of the CF Foundation and 66% of alleles were identified in this group. delta F508 mutation was found in 45%. We did not identify mutations in any of the remaining 7 patients.
Our results suggest that the majority of undetected mutations are associated with atypical phenotypes or that some patients in this series could have other diseases. We recommend to include mutation analysis in the evaluation of Chilean patients with CF. It is useful to establish prognosis and genetic counselling.
囊性纤维化(CF)是一种常染色体隐性疾病,由CFTR基因突变引起,该基因编码位于上皮细胞顶端表面的氯离子通道。这种蛋白质的主要作用是调节氯离子运输,其次是调节钠和水向细胞外空间的运输。已描述了900多种基因突变,它们在不同人群中的相对频率取决于种族起源。
报告对智利囊性纤维化患者进行分析的结果,分析其中20种常见突变的存在情况。
研究了57例已确诊或疑似患有CF的患者。使用商业检测方法通过聚合酶链反应同时鉴定20种突变和正常的ΔF508等位基因。
发现了8种突变。50例患者符合CF基金会共识小组提出的诊断标准,该组中鉴定出66%的等位基因。发现45%的患者存在ΔF508突变。其余7例患者均未发现突变。
我们的结果表明,大多数未检测到的突变与非典型表型相关,或者该系列中的一些患者可能患有其他疾病。我们建议在对智利CF患者的评估中纳入突变分析。这对于确定预后和进行遗传咨询很有用。